-- 水曜午前、米国預託証券(ADR)が上昇する中、アジア株は米国市場で取引され、S&Pアジア50 ADR指数は0.59%高の2,820.86となった。 北アジアでは、消費者金融会社のイーソン・テクノロジー(DXF)と教育会社の51トーク・オンライン・エデュケーション・グループ(COE)がそれぞれ5.3%高、5%高と上昇を牽引した。これに続き、フィンテック企業のマーセ(MAAS)とバイオ医薬品会社のザイラボ(ZLAB)がそれぞれ4.3%高、4%高となった。 一方、北アジアでは、フィンテック企業のAMTDデジタル(HKD)とオンラインゲーム開発会社のThe9(NCTY)がそれぞれ2%安、1.5%安と下落を牽引した。これに続き、電力会社の韓国電力(KEP)と電気自動車メーカーのNIO(NIO)がそれぞれ1.1%安、1%安となった。 南アジアでは、テクノロジー複合企業のSea(SE)とIT企業のWipro(WIT)がそれぞれ2.9%と2.7%上昇し、上昇を牽引しました。これに続いて、IT企業のInfosys(INFY)とSify Technologies(SIFY)がそれぞれ1.5%上昇しました。 一方、南アジアでは、製薬会社のDr. Reddy's Laboratories(RDY)が1.5%下落し、次いで通信事業者のTelekomunikasi Indonesia(TLK)とPLDT(PHI)がそれぞれ0.1%下落しました。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.